RLAYNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Relay Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$17.09+0.81 (+4.98%)

Close on Oct 19, 2026

Market cap: $3.47B
P/E (TTM): –
Dividend yield: –

Relay Therapeutics, Inc. balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31
Cash & Equivalents	84	126	146	154	283	449	43	422
Cash & Short-Term Investments	84	126	146	154	283	449	43	422
Receivables	–	–	–	0.31	0.40	75	–	–
Prepaid Expenses & Other	18	17	17	12	11	9.39	4.72	–
Other Current Assets	5.97	11	3.32	3.26	1.76	–	–	–
Total Current Assets	578	809	770	1,020	976	770	361	–
Property, Plant & Equipment	1.73	5.91	11	12	6.54	6.25	8.09	–
Gross Property, Plant & Equipment	23	35	34	30	21	17	15	–
Accumulated Depreciation	-22	-29	-24	-18	-14	-11	-6.98	–
Operating Lease Right-of-Use Assets	40	52	58	64	21	23	24	–
Intangible Assets	–	–	2.30	2.30	2.30	–	–	–
Total Assets	621	871	844	1,100	1,008	800	393	–
Accounts Payable	7.71	14	9.21	11	8.28	6.35	6.99	–
Accrued Expenses	14	21	15	23	14	5.76	3.75	–
Current Portion of Leases	3.77	5.73	4.96	4.28	1.84	1.52	1.25	–
Deferred Revenue (Current)	–	7.68	–	–	0.25	–	–	–
Other Current Liabilities	0.46	1.99	1.20	26	0.40	–	–	–
Total Current Liabilities	26	51	30	64	24	14	12	–
Long-Term Leases	29	43	49	53	21	23	24	–
Operating Lease Liabilities	32	49	53	58	23	24	25	–
Other Long-Term Liabilities	–	–	–	–	15	–	–	–
Total Liabilities	54	94	92	150	111	37	36	–
Preferred Stock	–	–	–	–	0	0	538	–
Common Stock	0.17	0.17	0.13	0.12	0.11	0.09	–	–
Additional Paid-In Capital	2,581	2,517	2,153	2,019	1,667	1,167	8.72	–
Retained Earnings	-2,015	-1,738	-1,401	-1,059	-768	-404	-189	–
Comprehensive Income & Other	0.73	-0.99	-0.20	-10	-1.09	0.06	0.33	–
Shareholders' Equity	567	778	752	950	898	763	-180	-111
Total Equity	567	778	752	950	898	763	-180	-111
Total Liabilities & Equity	621	871	844	1,100	1,008	800	393	–
Shares Outstanding(shares)	174	168	127	121	108	90	4.04	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -2999.4%
Net margin: -2763.6%
Return on equity, FY2025: -41.1%

Financial strength

Current ratio: 18.27
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 238.5%

Valuation

P/E ratio: –
Price to sales: 334.95
Price to book: 3.90
Dividend yield: –